(Q71191873)

English

Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects

scientific article published on 01 June 1996

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8681488%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8681488%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

pharmacodynamics

1 reference

based on heuristic

inferred from title

author name string

K A Nieforth

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8681488%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

R Nadeau

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8681488%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

I H Patel

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8681488%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

D Mould

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8681488%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

publication date

1 June 1996

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8681488%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

Clinical Pharmacology & Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8681488%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

59

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8681488%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8681488%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

636-646

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8681488%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

Virus interference. I. The interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990003-X

7 January 2021

Antiviral actions of interferon interferon-regulated cellular proteins and their surprisingly selective antiviral activities

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990003-X

7 January 2021

Functional role of type I and type II interferons in antiviral defense

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990003-X

7 January 2021

Interferon-alpha in malignant and viral diseases. A review

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990003-X

7 January 2021

cDNA structures and regulation of two interferon-induced human Mx proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990003-X

7 January 2021

The antiviral potentials of Mx proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990003-X

7 January 2021

Mx proteins: GTPases with antiviral activity

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990003-X

7 January 2021

Nuclear myxovirus-resistance protein Mx is a minor histocompatibility antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990003-X

7 January 2021

Double-blind randomized phase I study on the clinical tolerance and biological effects of natural and recombinant interferon-beta

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990003-X

7 January 2021

Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990003-X

7 January 2021

Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990003-X

7 January 2021

Time course of interferon levels, antiviral state, 2',5'-oligoadenylate synthetase and side effects in healthy men.

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990003-X

7 January 2021

Quantitation of interferon-induced Mx protein in whole blood lysates by an immunochemiluminescent assay: elimination of protease activity of cell lysates in toto.

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990003-X

7 January 2021

Influence of Human Serum Albumin Content in Formulations on the Bioequivalency of Interferon Alfa‐2a Given by Subcutaneous Injection in Healthy Male Volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990003-X

7 January 2021

Physiologic indirect response models characterize diverse types of pharmacodynamic effects

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990003-X

7 January 2021

Comparison of four basic models of indirect pharmacodynamic responses

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990003-X

7 January 2021

Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990003-X

7 January 2021

Resistance to influenza virus and vesicular stomatitis virus conferred by expression of human MxA protein

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990003-X

7 January 2021

Identifiers

10.1016/S0009-9236(96)90003-X

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8681488%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8681488%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q71191873&oldid=2143845648"